Abstract:Pulmonary hypertension (PH) is a progressive disease characterized by pulmonary vascular remodeling, sustained elevated pulmonary vascular resistance, and pulmonary arterial pressure, culminating in right heart failure and premature mortality. Decades of research have yielded significant strides in comprehending the molecular mechanisms involved in pulmonary vascular remodeling and PH, enabling the development of targeting drugs and clinical diagnosis optimization. Nevertheless, PH remains a complicated clinical syndrome with non-specific manifestations. Meanwhile, the existing drugs are not universally effective, being able to mitigate only clinical symptoms, but fail to preventing or reversing pathological vascular remodeling progress. Hence, the identification of new diagnostic markers and intervention targets remains paramount to diminish misdiagnosis and advance precision medicine. Epigenetic modifications play a pivotal role in pulmonary vascular remodeling and PH pathogenesis. RNA methylation, a reversible chemical modification of RNA, has recently gained much attention from researchers, demonstrating significant roles in the onset and progression of PH. This encompasses phenotypic switch of smooth muscle cells, dysfunction of endothelial cells, and inflammatory responses of monocytes/macrophages. Gene ablation of RNA methylation modulators in SuHx (SU5416+Hypoxia) mice shows reduced pulmonary vascular remodeling and improved hemodynamic parameters in vivo. Meanwhile, inhibition of RNA methylation modulators also improves the proliferation of vascular cells and activation of macrophages in vitro. In addition, numerous studies have underscored abnormal metabolic reprogramming as a universal hallmark of PH, such as increased glucose uptake, glycolysis, fatty acid oxidation, and glutamate metabolism. All these dysfunctions of metabolic reprogramming in various vascular and perivascular cells can exacerbate pulmonary vascular remodeling. Of note, a large number of studies have shown that inhibition of metabolic reprogramming could also reverse right heart dysfunction and vascular cell proliferation in vivo and in vitro. Thus, targeting the key modulators of RNA methylation and (or) metabolic reprogramming might be an effective method in PH treatment.With the rapid development of sequencing technology and further in-depth research on PH, increasing evidence has indicated that RNA methylation modification and metabolic reprogramming could regulate each other and jointly participate in various diseases. However, it remains unclear whether these processes synergistically promote the progression of PH. To that end, this review systematically introduces the main types and functions related to RNA methylation and metabolic reprogramming, comprehensively organizing recent advances in RNA methylation and metabolic reprogramming in PH pathogenesis. Furthermore, we outline the potential association of RNA methylation and metabolic reprogramming in synergistically regulating PH progression. We believe that a deeper understanding of the metabolic and epigenetic mechanisms underlying PH will furnish crucial insights for designing new therapeutics and advance our knowledge of PH pathogenesis.

METTL3-Driven m6A Modification of RBPJ Promotes Vascular Remodeling in Pulmonary Hypertension

Loss of M6a Demethylase ALKBH5 Alleviates Hypoxia-Induced Pulmonary Arterial Hypertension Via Inhibiting Cyp1a1 Mrna Decay

The M6a Methyltransferase METTL3 Promotes Hypoxic Pulmonary Arterial Hypertension Via Targeting PTEN

Methyltransferase Like 3-Mediated N6-methylatidin Methylation Inhibits Vascular Smooth Muscle Cells Phenotype Switching Via Promoting Phosphatidylinositol 3-Kinase Mrna Decay.

The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension

Methyltransferase-Like 3-Mediated N6-Methyladenosine RNA Methylation Regulates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Pyroptosis by Targeting PTEN

N6-methyladenosine-driven miR-143/145-KLF4 circuit orchestrates the phenotypic switch of pulmonary artery smooth muscle cells

Transcriptome-Wide N6-Methyladenosine Alternations in Pulmonary Arteries of Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats and Novel Therapeutic Targets

Regulation of Blood Pressure by METTL3 Via RUNX1b-eNOS Pathway in Endothelial Cells

RNA methylation, metabolic reprogramming and pulmonary hypertension

Smooth Muscle Ythdf2 Abrogation Ameliorates Pulmonary Vascular Remodeling by Regulating Myadm Transcript Stability

SEDT2/METTL14-mediated M6a Methylation Awakening Contributes to Hypoxia-Induced Pulmonary Arterial Hypertension in Mice.

RNA m6A methylation and regulatory proteins in pulmonary arterial hypertension

LncRNA MYOSLID Contributes to PH Via Targeting BMPR2 Signaling in Pulmonary Artery Smooth Muscle Cell

Abstract 9529: METTL3 Mediates Ang-II Induced Cardiac Hypertrophy Through Accelerating Pri-miR-221/222 Maturation in M6a Way

METTL3-mediated m6A RNA methylation induces the differentiation of lung resident mesenchymal stem cells into myofibroblasts via the miR-21/PTEN pathway

TRB3 mediates vascular remodeling by activating the MAPK signaling pathway in hypoxic pulmonary hypertension

EP3 Receptor Deficiency Attenuates Pulmonary Hypertension Through Suppression of Rho/TGF-β1 Signaling

Comprehensive analysis of the expression of N6-methyladenosine RNA methylation regulators in pulmonary artery hypertension

m6A Modification-mediated GRAP Regulates Vascular Remodeling in Hypoxic Pulmonary Hypertension

Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension